JP2011506587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506587A5 JP2011506587A5 JP2010538869A JP2010538869A JP2011506587A5 JP 2011506587 A5 JP2011506587 A5 JP 2011506587A5 JP 2010538869 A JP2010538869 A JP 2010538869A JP 2010538869 A JP2010538869 A JP 2010538869A JP 2011506587 A5 JP2011506587 A5 JP 2011506587A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- liquid
- active ingredient
- composition according
- protein active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0759971A FR2925333B1 (fr) | 2007-12-19 | 2007-12-19 | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
| FR0759971 | 2007-12-19 | ||
| PCT/FR2008/052357 WO2009083686A1 (fr) | 2007-12-19 | 2008-12-18 | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506587A JP2011506587A (ja) | 2011-03-03 |
| JP2011506587A5 true JP2011506587A5 (OSRAM) | 2012-02-16 |
| JP5676272B2 JP5676272B2 (ja) | 2015-02-25 |
Family
ID=39671377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538869A Active JP5676272B2 (ja) | 2007-12-19 | 2008-12-18 | 消化酵素から保護される少なくとも１種のタンパク質活性成分を含む医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8309123B2 (OSRAM) |
| EP (1) | EP2234598B1 (OSRAM) |
| JP (1) | JP5676272B2 (OSRAM) |
| KR (2) | KR101592609B1 (OSRAM) |
| CN (1) | CN101917967B (OSRAM) |
| AP (1) | AP3573A (OSRAM) |
| AR (1) | AR069847A1 (OSRAM) |
| AU (1) | AU2008345474B2 (OSRAM) |
| BR (1) | BRPI0821373B8 (OSRAM) |
| CA (1) | CA2709899C (OSRAM) |
| EA (1) | EA023107B1 (OSRAM) |
| FR (1) | FR2925333B1 (OSRAM) |
| IL (1) | IL206364A (OSRAM) |
| MA (1) | MA31927B1 (OSRAM) |
| MX (1) | MX2010006927A (OSRAM) |
| TN (1) | TN2010000290A1 (OSRAM) |
| TW (1) | TWI461226B (OSRAM) |
| WO (1) | WO2009083686A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120035103A1 (en) * | 2010-01-29 | 2012-02-09 | Pillion Dennis J | Method for administration of insulin and pharmaceutical composition thereof |
| AU2015294912A1 (en) | 2014-07-30 | 2017-02-16 | Sun Pharmaceutical Industries Limited | Dual-chamber pack |
| US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
| EP3137060B2 (en) | 2014-05-01 | 2023-12-20 | Sun Pharmaceutical Industries Ltd | Extended release suspension compositions |
| US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
| US20180104197A9 (en) | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
| US11331376B2 (en) * | 2014-11-04 | 2022-05-17 | Innopharmax, Inc. | Oral administration of unstable or poorly-absorbed drugs |
| US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
| US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
| FR3120189B1 (fr) * | 2021-03-01 | 2024-11-29 | Farid Bennis | Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE36225B1 (en) | 1971-01-28 | 1976-09-15 | Nat Res Dev | Improvements relating to insulin derivatives |
| US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
| EP0179904A1 (en) | 1984-05-09 | 1986-05-07 | Medaphore Inc. | Oral insulin and a method of making the same |
| US4693433A (en) * | 1986-06-06 | 1987-09-15 | Merrill David Martin | Unwind stand for web rolls |
| US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| CA2199005A1 (en) * | 1994-09-01 | 1996-03-07 | Emile Bourland (Deceased) | Compositions and methods for delivery of polypeptides |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
| ES2293875T3 (es) * | 1997-10-01 | 2008-04-01 | Novadel Pharma Inc. | Aerosol bucal no polar. |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| US6531648B1 (en) * | 1998-12-17 | 2003-03-11 | Syngenta Participations Ag | Grain processing method and transgenic plants useful therein |
| ATE216223T1 (de) * | 1999-01-27 | 2002-05-15 | Idea Ag | Transnasaler transport bzw. impfung mit hochadaptierbaren trägern |
| SE9904121D0 (sv) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobe biomolecular structure |
| US6531112B2 (en) * | 2000-05-15 | 2003-03-11 | Delrx Pharmaceutical Corporation | Formulations for administering calcitonin and processes for preparing the same |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| CN1335182A (zh) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
| GB0119859D0 (en) * | 2001-08-15 | 2001-10-10 | Qinetiq Ltd | Eye tracking system |
| US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| WO2005113008A1 (en) * | 2004-05-21 | 2005-12-01 | Mediplex Corp. | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| CN103223160B (zh) * | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| JP2008509145A (ja) * | 2004-08-03 | 2008-03-27 | エミスフィアー テクノロジーズ インコーポレイテッド | 抗糖尿病性経口インスリン−ビグアニドの組み合わせ |
| AU2006249480A1 (en) | 2005-05-23 | 2006-11-30 | Sdg, Inc. | Lipid construct for delivery of insulin to a mammal |
| EP1924248B1 (en) * | 2005-09-15 | 2014-10-22 | Council of Scientific and Industrial Research | Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides |
| CA2670355A1 (en) * | 2005-11-21 | 2008-04-24 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
| WO2007121318A2 (en) * | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
-
2007
- 2007-12-19 FR FR0759971A patent/FR2925333B1/fr active Active
-
2008
- 2008-12-18 KR KR1020107013390A patent/KR101592609B1/ko active Active
- 2008-12-18 EP EP08867946.9A patent/EP2234598B1/fr active Active
- 2008-12-18 EA EA201070746A patent/EA023107B1/ru unknown
- 2008-12-18 CA CA2709899A patent/CA2709899C/fr active Active
- 2008-12-18 WO PCT/FR2008/052357 patent/WO2009083686A1/fr not_active Ceased
- 2008-12-18 AU AU2008345474A patent/AU2008345474B2/en not_active Ceased
- 2008-12-18 BR BRPI0821373A patent/BRPI0821373B8/pt active IP Right Grant
- 2008-12-18 MX MX2010006927A patent/MX2010006927A/es active IP Right Grant
- 2008-12-18 KR KR1020157032578A patent/KR20150132887A/ko not_active Ceased
- 2008-12-18 AP AP2010005298A patent/AP3573A/xx active
- 2008-12-18 CN CN200880125189XA patent/CN101917967B/zh active Active
- 2008-12-18 JP JP2010538869A patent/JP5676272B2/ja active Active
- 2008-12-19 US US12/339,310 patent/US8309123B2/en active Active
- 2008-12-19 AR ARP080105568A patent/AR069847A1/es unknown
- 2008-12-19 TW TW097149879A patent/TWI461226B/zh not_active IP Right Cessation
-
2010
- 2010-06-14 IL IL206364A patent/IL206364A/en active IP Right Grant
- 2010-06-18 MA MA32934A patent/MA31927B1/fr unknown
- 2010-06-18 TN TN2010000290A patent/TN2010000290A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506587A5 (OSRAM) | ||
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2010047612A5 (OSRAM) | ||
| ES2610411T3 (es) | Sustrato sólido poroso disgregable para aplicaciones para el cuidado de la salud personal | |
| JP6040218B2 (ja) | 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠 | |
| JP2019131596A5 (OSRAM) | ||
| JP2004533999A5 (OSRAM) | ||
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| JP2013532729A5 (OSRAM) | ||
| JP2012502037A5 (OSRAM) | ||
| JP2016511753A5 (OSRAM) | ||
| KR101947198B1 (ko) | 수난용성 약물 함유 의약 조성물 | |
| JP2009544665A5 (OSRAM) | ||
| JP2013505233A5 (OSRAM) | ||
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP2009517411A5 (OSRAM) | ||
| CN104490909B (zh) | 一种咖啡酸衍生物在制备具有抗rsv病毒作用的药物中的应用 | |
| WO2011073408A3 (en) | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | |
| WO2007144083A3 (de) | Ache-nmda-kombinationswafer | |
| JP2011530540A5 (OSRAM) | ||
| CN107530294A (zh) | 含有质子泵抑制剂的肠溶包衣丸剂 | |
| JP2009508916A5 (OSRAM) | ||
| WO2007128495A3 (en) | Solid pharmaceutical composition of gabapentin | |
| JP2019521178A5 (OSRAM) | ||
| RU2017145602A (ru) | Жидкие композиции целекоксиба для перорального введения |